Cargando…

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

BACKGROUND: ABP 501 is being developed as a biosimilar to adalimumab. Comprehensive comparative analytical characterization studies have been conducted and completed. OBJECTIVE: The objective of this study was to assess analytical similarity between ABP 501 and two adalimumab reference products (RPs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jennifer, Eris, Tamer, Li, Cynthia, Cao, Shawn, Kuhns, Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972872/ https://www.ncbi.nlm.nih.gov/pubmed/27461107 http://dx.doi.org/10.1007/s40259-016-0184-3

Ejemplares similares

Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
por: Hutterer, Katariina M., et al.
Publicado: (2019)

Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab
por: Seo, Neungseon, et al.
Publicado: (2018)

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
por: Velayudhan, Jyoti, et al.
Publicado: (2016)

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

Analytical and Functional Similarity of the Biosimilar Candidate ABP 654 to Ustekinumab Reference Product
por: Cantin, Greg, et al.
Publicado: (2023)

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Cingolani, Linda, et al.
Publicado: (2021)

A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
por: Markus, Richard, et al.
Publicado: (2019)

Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
por: Saleem, Ramsey, et al.
Publicado: (2020)

Analytical Similarity Assessment of ABP 959 in Comparison with Eculizumab Reference Product
por: Hutterer, Katariina M., et al.
Publicado: (2021)

T.06.4 LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY
por: Cingolani, A., et al.
Publicado: (2022)

Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
por: Jassem, Shea, et al.
Publicado: (2019)

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
por: Cohen, Stanley, et al.
Publicado: (2017)

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study
por: Barberio, Brigida, et al.
Publicado: (2021)

Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
por: Zhang, Erhui, et al.
Publicado: (2020)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis
por: Becciolini, Andrea, et al.
Publicado: (2022)

Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®
por: Magnenat, Laurent, et al.
Publicado: (2016)

Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
por: Waller, Cornelius F., et al.
Publicado: (2010)

A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab
por: Kaur, Primal, et al.
Publicado: (2017)

Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
por: Waller, Cornelius F., et al.
Publicado: (2010)

The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
por: Goldschmidt, Jerome, et al.
Publicado: (2020)

Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®)
por: Kwon, Joon-Cheol, et al.
Publicado: (2021)

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2020)

Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity
por: Kang, Jia, et al.
Publicado: (2020)

AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
por: Kolberg, Hans-Christian, et al.
Publicado: (2019)

Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single‐Blind, Single‐Dose, Parallel‐Group Study in Healthy Subjects
por: Chow, Vincent, et al.
Publicado: (2019)

A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
por: Reinisch, Walter, et al.
Publicado: (2021)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Correction to: AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Navigating adalimumab biosimilars: an expert opinion
por: Abitbol, Vered, et al.
Publicado: (2023)

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
por: Cohen, Stanley, et al.
Publicado: (2019)

Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
por: Kolberg, Hans-Christian, et al.
Publicado: (2021)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®
por: Xu, Yanpeng, et al.
Publicado: (2019)

A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects
por: Hanes, Vladimir, et al.
Publicado: (2017)

Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab
por: Dickson, Sean R., et al.
Publicado: (2023)

Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method
por: Kim, Hyunsoo, et al.
Publicado: (2023)

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
por: Cao, Di, et al.
Publicado: (2023)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7a2j9au785jsf161brtha7crb0